Genfit SA ( (GNFT) ) just unveiled an announcement.
On April 29, 2025, GENFIT announced the publication of its 2024 Universal Registration Document and Annual Report on Form 20-F. These documents, filed with the Autorité des marchés financiers and the U.S. Securities and Exchange Commission respectively, are now available to the public. The reports include comprehensive financial and management information, corporate governance details, and auditor reports. This announcement underscores GENFIT’s commitment to transparency and regulatory compliance, potentially strengthening its position in the biopharmaceutical industry and providing stakeholders with valuable insights into its operations and strategic direction.
Spark’s Take on GNFT Stock
According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.
Genfit SA’s stock score reflects significant financial challenges, particularly in profitability and cash flow. While the stock may be undervalued, negative technical trends and the absence of earnings call guidance contribute to a cautious outlook. Improvements in financial health and clearer strategic direction are needed for a more favorable assessment.
To see Spark’s full report on GNFT stock, click here.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases. With a history of over two decades in liver disease research, the company has a diverse R&D portfolio targeting conditions such as Acute-on-Chronic Liver Failure (ACLF), cholangiocarcinoma, urea cycle disorder, and organic acidemia. GENFIT is also involved in diagnostics, with products like NIS2+® for Metabolic dysfunction-associated steatohepatitis and TS-01 for blood ammonia levels. The company is headquartered in Lille, France, with offices in Paris, Zurich, and Cambridge, MA, and is listed on Nasdaq and Euronext.
YTD Price Performance: -4.20%
Average Trading Volume: 12,696
Technical Sentiment Signal: Buy
Current Market Cap: $192.2M
See more data about GNFT stock on TipRanks’ Stock Analysis page.